The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-((2S,3S,4R)-1-(4-(((3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-(3-methoxypropoxy)-3-methylpyrrolidin-2-yl)acetic acid ID: ALA5285988
Max Phase: Preclinical
Molecular Formula: C29H40ClN3O6
Molecular Weight: 562.11
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: COCCCO[C@H]1CN(c2ccc(O[C@@H]3CCN(c4cc(OC)ncc4Cl)C[C@H]3C)cc2)[C@@H](CC(=O)O)[C@@H]1C
Standard InChI: InChI=1S/C29H40ClN3O6/c1-19-17-32(25-14-28(37-4)31-16-23(25)30)11-10-26(19)39-22-8-6-21(7-9-22)33-18-27(38-13-5-12-36-3)20(2)24(33)15-29(34)35/h6-9,14,16,19-20,24,26-27H,5,10-13,15,17-18H2,1-4H3,(H,34,35)/t19-,20+,24+,26-,27+/m1/s1
Standard InChI Key: CEBGUURUAFCIGS-UAVGYUILSA-N
Molfile:
RDKit 2D
39 42 0 0 0 0 0 0 0 0999 V2000
-1.0790 1.3917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3644 1.8040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3474 1.3920 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3474 0.5669 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3626 0.1550 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0790 0.5632 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0621 0.1543 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.8155 0.4898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3675 -0.1231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9551 -0.8374 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1482 -0.6659 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5651 -1.2490 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7786 -2.0456 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1954 -2.6286 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.5751 -2.2590 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.1921 -0.1231 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.6045 0.5910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.4292 0.5910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8415 1.3052 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.6662 1.3052 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.0785 2.0194 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7931 1.8040 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.5073 1.3917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5073 0.5669 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2214 0.1547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.9357 0.5669 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.9357 1.3917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2214 1.8040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2214 2.6286 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6499 0.1547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6502 -0.6699 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.3625 -1.0804 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.0770 -0.6679 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-6.0785 0.1526 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.3671 0.5688 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.3671 1.3934 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
-5.3625 -1.9051 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.6483 -2.3174 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3674 -1.5516 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
6 5 2 0
1 6 1 0
7 4 1 0
7 8 1 0
8 9 1 0
9 10 1 0
10 11 1 0
11 7 1 0
11 12 1 6
12 13 1 0
13 14 1 0
13 15 2 0
9 16 1 6
16 17 1 0
17 18 1 0
18 19 1 0
19 20 1 0
20 21 1 0
1 22 1 0
23 22 1 6
24 23 1 0
25 24 1 0
26 25 1 0
27 26 1 0
28 27 1 0
23 28 1 0
28 29 1 1
30 26 1 0
31 30 2 0
32 31 1 0
33 32 2 0
34 33 1 0
35 34 2 0
30 35 1 0
35 36 1 0
32 37 1 0
37 38 1 0
10 39 1 1
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 562.11Molecular Weight (Monoisotopic): 561.2606AlogP: 4.76#Rotatable Bonds: 12Polar Surface Area: 93.59Molecular Species: ACIDHBA: 8HBD: 1#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 3.39CX Basic pKa: 5.78CX LogP: 2.90CX LogD: 1.45Aromatic Rings: 2Heavy Atoms: 39QED Weighted: 0.37Np Likeness Score: -0.35
References 1. Jurica EA, Wu X, Williams KN, Haque LE, Rampulla RA, Mathur A, Zhou M, Cao G, Cai H, Wang T, Liu H, Xu C, Kunselman LK, Antrilli TM, Hicks MB, Sun Q, Dierks EA, Apedo A, Moore DB, Foster KA, Cvijic ME, Panemangalore R, Khandelwal P, Wilkes JJ, Zinker BA, Robertson DG, Janovitz EB, Galella M, Li YX, Li J, Ramar T, Jalagam PR, Jayaram R, Whaley JM, Barrish JC, Robl JA, Ewing WR, Ellsworth BA.. (2023) Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities., 85 [PMID:37030194 ] [10.1016/j.bmc.2023.117273 ]